淋巴细胞与单核细胞比值对接受索拉非尼治疗的日本分化型甲状腺癌患者的预后价值
Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.
作者信息
Nakamoto Shogo, Ikeda Masahiko, Kubo Shinichiro, Yamamoto Mari, Yamashita Tetsumasa, Kuwahara Chihiro
机构信息
Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
出版信息
Cancer Diagn Progn. 2021 Nov 3;1(5):491-498. doi: 10.21873/cdp.10066. eCollection 2021 Nov-Dec.
BACKGROUND/AIM: We investigated the efficacy and safety of sorafenib in Japanese patients and the prognostic value of systemic immunity markers for predicting clinical outcomes after sorafenib therapy in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC).
PATIENTS AND METHODS
We retrospectively evaluated 26 patients with RR-DTC who underwent sorafenib therapy between July 2014 and December 2020. The systemic immunity markers were calculated from blood cell counts.
RESULTS
The median overall survival (OS) was 2,002 days, and the clinical benefit rate was 80.8%. The high lymphocyte-to-monocyte ratio (LMR) group had significantly longer OS than the low LMR group (hazard ratio=0.21; 95% confidence interval=005-0.88; log-rank p=0.019). Adverse events observed in this study were acceptable, and no new safety signals associated with sorafenib were found.
CONCLUSION
Sorafenib therapy is efficacious and safe for Japanese patients with RR-DTC, and baseline LMR may be useful as a sorafenib therapy prognostic marker.
背景/目的：我们研究了索拉非尼在日本患者中的疗效和安全性，以及全身免疫标志物对放射性碘难治性分化型甲状腺癌（RR-DTC）患者接受索拉非尼治疗后临床结局的预测价值。
患者与方法
我们回顾性评估了2014年7月至2020年12月期间接受索拉非尼治疗的26例RR-DTC患者。全身免疫标志物由血细胞计数计算得出。
结果
中位总生存期（OS）为2002天，临床获益率为80.8%。高淋巴细胞与单核细胞比值（LMR）组的OS显著长于低LMR组（风险比=0.21；95%置信区间=0.05-0.88；对数秩检验p=0.019）。本研究中观察到的不良事件是可接受的，未发现与索拉非尼相关的新的安全信号。
结论
索拉非尼治疗对日本RR-DTC患者有效且安全，基线LMR可能作为索拉非尼治疗的预后标志物。
Zotero 插件